Subconjunctival ranibizumab for squamous cell carcinoma of the conjunctiva with corneal extension
Teng C, Chin K, Finger P. Subconjunctival ranibizumab for squamous cell carcinoma of the conjunctiva with corneal extension. British Journal Of Ophthalmology 2009, 93: 837. PMID: 19471005, DOI: 10.1136/bjo.2008.156489.Peer-Reviewed Original ResearchEffect of Subconjunctival Bevacizumab on Primary Pterygium
Teng CC, Patel NN, Jacobson L. Effect of Subconjunctival Bevacizumab on Primary Pterygium. Cornea 2009, 28: 468-470. PMID: 19411971, DOI: 10.1097/ico.0b013e31818d382d.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabConjunctivaHumansMaleMiddle AgedPterygiumTreatment OutcomeVascular Endothelial Growth Factor AConceptsPrimary pterygiumSubconjunctival bevacizumabEfficacy of bevacizumabNasal primary pterygiumFurther long-term studiesSymptoms of irritationDegree of vascularityML of bevacizumabSurgical excisionTopical proparacaineTotal regressionTopical treatmentArtificial tearsClinical signsPterygium pathogenesisBevacizumab resultsWeeks postinjectionBevacizumabWeek 2PterygiumWeek 7Long-term studiesGrowth factorIrritationShort-term decrease